PF-Atlas › Clinical Trials › NCT07674745

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

Therapeutic Plasma Exchange · Phase 2

Registry ID
NCT07674745
Phase
Phase 2
Status
Not yet recruiting
Drug / intervention
Therapeutic Plasma Exchange
Sponsor
University of Alabama at Birmingham
Start
2026-10-01
Enrollment
52
Locations
9

About this trial

This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).

View NCT07674745 on ClinicalTrials.gov →

Explore related

All Therapeutic Plasma Exchange trialsAll IPF trials

Related trials

Therapeutic Plasma exchange — NCT04492501
Medical disclaimer. This page summarizes public trial data for NCT07674745 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.